# Foxiga Korea Local Phase 4 Study

Study · id `cardio:ct-nct02564926` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02564926](<https://clinicaltrials.gov/study/NCT02564926>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02564926

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 125 participants.

## Technical summary

Registry record NCT02564926. Randomized; no masking; primary purpose treatment. Start 2016-01-05 (actual); primary completion 2018-01-15 (actual). Results posted on 2019-08-20.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 125 participants (enrolled count; ClinicalTrials.gov record NCT02564926, source copy `cardio:ctgov-nct02564926-2019-08-20`, retrieved 2026-10-26)
- Started: 2016-01-05 (actual) (ClinicalTrials.gov record NCT02564926, source copy `cardio:ctgov-nct02564926-2019-08-20`, retrieved 2026-10-26)
- Primary completion: 2018-01-15 (actual) (ClinicalTrials.gov record NCT02564926, source copy `cardio:ctgov-nct02564926-2019-08-20`, retrieved 2026-10-26)
- Completion: 2018-01-15 (actual) (ClinicalTrials.gov record NCT02564926, source copy `cardio:ctgov-nct02564926-2019-08-20`, retrieved 2026-10-26)
- Results first posted: 2019-08-20 (ClinicalTrials.gov record NCT02564926, source copy `cardio:ctgov-nct02564926-2019-08-20`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT02564926, source copy `cardio:ctgov-nct02564926-2019-08-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02564926-2019-08-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Foxiga Korea Local Phase 4 Study
- Acronym: BEYOND
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Dapagliflozin
- Intervention (Drug): Glimepiride
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Dapagliflozin (`cardio:dapagliflozin`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: d69ecf2d17589f31a9e837e3ed0ce9c3fe5b68af71506be9f5d0f15bc40f728b
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
